Results 81 to 90 of about 249 (106)

Safety and Efficacy of Dotinurad on Uric Acid in Patients With Chronic Kidney Disease With Estimated Glomerular Filtration Rate Below 25 mL/Min/1.73 m². [PDF]

Cureus
Mima A, Gotoda H, Lee S.
europepmc   +1 more source

Exploratory Mediation-Informed Analysis and Dose-Response Analysis of Uric Acid Reduction and Kidney Outcomes in SGLT2 Inhibitor Therapy Compared to Allopurinol. [PDF]

Med Sci (Basel)
Jámbor T, Tallósy SP, Lantos T, Szabó A, Fejes R.   +4 more
europepmc   +1 more source

Cost-effectiveness analysis of dotinurad compared to febuxostat for gout with hyperuricemia in China: a modeling study

Ke Wang, Mingye Zhao, Wenxi Tang, Di Zhang   +3 more
core   +1 more source

Advances in the management of gout: From current strategies to emerging therapies. [PDF]

J Int Med Res
Zhao Q, Dai X.
europepmc   +1 more source

Efficacy and safety of urate-lowering therapies in asymptomatic hyperuricaemia: a systematic review and network meta-analysis of key clinical outcomes. [PDF]

Ann Med
Yi Y, Yang J, Chen Y, Liu H, Deng Y.
europepmc   +1 more source

Impact of Dotinurad on Uric Acid Control and Kidney Function in Patients with Stage G3–G5 CKD: A Propensity-Matched Analysis

David Clark, Sophia Nguyen, Oliver Grant
core   +1 more source

Role of urate transporters in the kidneys and intestine in uric acid homeostasis. [PDF]

Kidney Res Clin Pract
Kim SH, Shin J, Son HE, Kang DH.
europepmc   +1 more source

Molecular mechanism of drug inhibition of URAT1. [PDF]

Nat Commun
Yu Z, Hu T, Su J, Zhao J, Li R, Ma Q, Chen Q, Bai Q, Dong Y, Yuan P, Li N, Zhang XC, Zhao Y.   +12 more
europepmc   +1 more source

Gout therapy updated. [PDF]

Ther Adv Musculoskelet Dis
McCarty KL, Gaffo AL, Diaz-Torne C.
europepmc   +1 more source